Synagis Clinic

Respiratory Syncytial Virus Protection in Northern California

• Each year, 125,000 infants in the United States are hospitalized with severe RSV infections, making it the leading cause of infant hospitalization in the country.
• The Synagis Clinic at UCSF Benioff Children's Hospital Oakland provides RSV protection using Synagis, an FDA-approved monoclonal anti-RSV antibody.

Special RSV Considerations

• Because the Synagis shot is not part of the normal immunization program and is considered an antibody against RSV, referral or consultation is required. Ongoing care and monitoring may also be needed.
• Infants and toddlers at the highest risk for complications related to RSV include those with chronic lung disease, congenital heart disease, immunodeficiency disorders, neuromuscular disorders, and those who were born at 32 weeks premature (or before).

Eligibility for the Synagis Clinic

• Eligibility is dependent on your child's condition and her or his age at the time of the RSV season (November through March) and who meet the following criteria:
• Infants younger than 2 years with chronic lung disease (CLD) who have required medical therapy for their CLD within six months of the start of the RSV season.
• Infants who were born at less than 28 weeks gestational age and who are younger than 1 year at the start of the RSV season.
• Infants who were born at 29 to 32 weeks gestational age and who are younger than 6 months at the start of RSV season.
• Infants who were born at 32 to 34 6/7 weeks gestational age.